Sabroxy® for Insulin Resistance and Mild Cognitive Impairment
This study is testing if a dietary supplement called Sabroxy® can help adults with mild cognitive impairment (problems with memory or thinking) and insulin resistance (when your body doesn't respond well to insulin, a hormone that helps control blood sugar). You might be able to join if you are 40-80 years old, have certain blood sugar and insulin resistance levels, and a specific score on a memory test (MoCA score less than 26). The study will measure changes in your insulin resistance using a test called HOMA-IR. The current status of this study is unclear, and it plans to enroll 140 participants.
- Study design
- This is a randomized, double-blind, placebo-controlled study involving 120 participants. You will either receive Sabroxy® or an inactive placebo.
- What's involved
- You would take a capsule once daily after breakfast with water for 8 weeks. You will have assessments at prescreening and at Week 8.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your insulin resistance will be measured at prescreening and at Week 8.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change in Insulin Resistance as Assessed by HOMA-IRPrescreening -14 days and Week 8
Insulin resistance will be evaluated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and fasting insulin levels. The objective is to determine the mean change in HOMA-IR from baseline to Week 8 between the Sabroxy® and placebo groups.